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A B S T R A C TObjectives: To examine cumulative survival and Medicaid-paid
expenses associated with multiple courses of transarterial chemo-
embolization (TACE) as primary treatment for hepatocellular
carcinoma (HCC). Methods: Medicare enrollees diagnosed with pri-
mary HCC from 2000 to 2007, ever treated with TACE, but not trans-
plant/resection, followed through 2009 by using the Surveillance,
Epidemiology and End-Results Program and linked Medicare data-
bases. Cumulative all-cause/HCC-related survival was estimated by
using multivariate Cox proportional hazards models stratiﬁed by the
total number of TACE treatments. Multivariate weighted Cox regres-
sions estimated the average risk of mortality faced with nonpropor-
tional hazards. Lin’s inverse probability-weighted least squares
regression method estimated cumulative Medicare expenditures
adjusted for censoring and covariates. Results: Of 1228 patients, 34%
were stage 1, 16% stage 2, 19% stage 3, 6% stage 4, and 26% unstaged.
About 44% were aged 65 to 75 years, 69% were men, and 72% were
Caucasian. Over half (57%) of the patients received one course, 24%
two, 11% three, and 8% four courses of TACE. One-course patients
incurred an average $74,788 (95% conﬁdence interval [CI] $71,890–see front matter Copyright & 2013, International S
r Inc.
1016/j.jval.2013.03.1630
rx.umaryland.edu.
ndence to: Ian M. Breunig, Pharmaceutical Health S
oor, Baltimore, MD 21201, USA.$77,686), two-course patients $101,126 (95% CI $94,395–$107,856),
three-course patients $111,776 (95% CI $101,931–$121,621), and four-
plus-course patients $148,878 (95% CI $136,346–$161,409). One-course
patients lived (all-cause) an average 1.86 (95% CI 1.82–1.90), two-
course patients 2.09 (95% CI 2.05–2.13), three-course patients 2.81
(95% CI 2.66–2.97), and four-plus-course patients 3.06 (95% CI 2.95–
3.18) years after diagnosis. Average risk of all-cause mortality was not
signiﬁcantly different between one/two courses or three/four-plus
courses. Conclusions: Cumulative Medicare expenditures nearly
doubled from one-course to four-plus-course patients. On average,
four-plus-course patients lived over one more year than did one-
course patients. Physician/patient decisions should be balanced with
consideration of efﬁcient use of limited resources, but payer’s inter-
vention in physician discretion may not be important in this setting.
Keywords: cost-effectiveness, hepatocellular carcinoma, SEER-
Medicare, survival, transarterial chemoembolization.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Hepatocellular carcinoma (HCC) is the sixth most common
cancer in the world and was the third most common cause of
cancer-related death in 2008 [1]. While the prevalence of HCC is
highest in developing countries, incidence in the United States
has tripled between 1975 and 2005 from 1.6 to 4.9 incidences per
100,000 inhabitants [2]. HCC is an age-dependent cancer that
peaks in incidence between 75 and 79 years of age [3]. The
hepatitis B and C viruses are the main risk factor for HCC because
they promote cirrhosis, which is found in 80% to 90% of HCC
cases [4]. Incidence is expected to continue rising in the next few
decades because of current trends related to the etiology of HCC
as well as an aging population [4]. Recent advances in oncology
have led to greater rates of early detection of HCC and more
effective treatment [5], yet most HCC is still diagnosed at
intermediate or advanced stages for which no curative therapy
has been established [6,7].In early stages of HCC, transplantation, surgical resection, and
percutaneous ablation are considered to be potentially curative
therapies [5]. Patients in early to intermediate stages, however,
are often precluded from these procedures, for instance, because
of tumor size, number of lesions, or complicating liver diseases
[8,9]. In this case, transarterial chemoembolization (TACE) is
often a ﬁrst-line therapy that has been shown to positively
impact survival, although overall survival beneﬁt is largely
dependent on the patients’ baseline clinical characteristics [5].
For patients also eligible for ablation, concomitant TACE treat-
ments have been shown recently to be more effective than
ablative therapy alone, providing overall survival rates similar
to that of surgical resection [10,11]. With TACE, chemotherapeutic
agents—commonly doxorubicin or cisplatin [12]—are concen-
trated and isolated at the tumor site while blocking the primary
artery feeding the tumor [7]. Because TACE can cause liver
damage, patients with preserved liver function are carefully
selected for the treatment [7,12]. Eligible patients often achieveociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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between three and four courses [12–15].
Changes in demographics and expanding therapeutic fron-
tiers including TACE necessitate increased attentiveness of
the long-term costs of cancer for payer organizations. Lang
et al. [16] conservatively estimated that total health care cost
per patient with HCC was an average $29,354 in 2006 US dollars
($34,947 in 2011 US dollars). The cost implications of HCC are
particularly relevant for Medicare because many patients with
HCC are eligible for Medicare because of age or other qualifying
conditions.
Much of the evidence on the effectiveness of TACE comes
from randomized clinical trials that often represent nontypical
demographics and risk factors. Randomized clinical trials have
yet to produce evidence for the effectiveness of repeated courses
of TACE in treating HCC, possibly because it is difﬁcult to
establish intent to treat when additional courses of TACE are
continued according to tumor response. No observational study
has evaluated the survival beneﬁt associated with repeated TACE
treatments for HCC. Moreover, health care organizations have an
interest in knowing the costs of TACE because there are no such
evaluations in the populations for which it is most treated. The
objective of this study was to examine cumulative survival across
Medicare patients who received multiple courses of TACE to treat
HCC and examine its association with long-term direct medical
costs to Medicare. Real-world evidence will not only inform
further analysis of emerging therapies such as TACE but also
help guide coverage and budget decisions by payers and pro-
viders for patients with HCC at different stages.Methods
Data Source
The National Cancer Institute’s Surveillance, Epidemiology and
End Results (SEER)-Medicare-linked database collects clinical
information on incident-based cancer diagnoses from cancer
registries covering nearly 26% of the U.S. population. Data
collected include demographic characteristics, date of diagnosis,
details about the cancer (e.g., histology, stage, and grade), and
cause of death, if applicable. Medicare enrollment and claims ﬁles
from Parts A (inpatient), B (provider), and D (drugs) are linked to
SEER such that information can be collected regarding utilization,
particularly types and timing of treatments undertaken, as well
as underlying comorbidity. The database has been found repre-
sentative of the national population and is described in detail
elsewhere [17] (http://seer.cancer.gov).
We selected patients with primary HCC initially diagnosed
between January 1, 2000, and December 31, 2007. Patients were
excluded if they were enrolled in a health maintenance organ-
ization (HMO) within 12 months prior to the diagnosis of HCC.
This was to eliminate possible censoring of information due to
switching between an HMO and Part A/B enrollment. Patients
were also excluded if they had an unknown diagnosis month or
year, had a history of other cancers within 5 years prior to
diagnosis, or for whom cancer was diagnosed upon death. Eligible
patients were followed until the week of death or until censored
because of the loss of Part A/B coverage, HMO enrollment, or
December 31, 2009.Survival
Survival was calculated as the number of weeks from diagnosis to
death. Mortality was deﬁned as all-cause or as HCC-related if the
cause of death was indicated as “liver.”TACE Treatments
The sample consists of all patients with HCC who met the
inclusion and exclusion criteria above and had undergone at
least one course of TACE in the follow-up period. Patients who
received transplant or resection in the follow-up period were
excluded (n ¼ 228) because these therapies dominate alternative
therapies in the Barcelona Clinic Liver Cancer staging system, the
most widely used system for staging and treatment [5,7]. TACE is
often used to reduce the dropout rate for patients on the waiting
list for liver transplantation (bridge-therapy) or to downstage
patients not initially meeting the criteria for transplantation or
resection eligibility [18,19]. Patients were not precluded from the
receipt of percutaneous ablation, systemic chemotherapy, or
radiation therapy before or after their TACE treatment(s). A large
fraction of TACE patients had undertaken multiple courses of
TACE throughout the follow-up period. We delineate patients
who received two, three, or four or more TACE treatments from
those who received only one.
Patient Characteristics
Age, sex, and race/ethnicity were recorded for all patients at
diagnosis. Patients were categorized into four age brackets:
younger than 65 years, 65 to 74 years, 75 to 84 years, and older
than 84 years. Race/ethnicity was categorized as Caucasian,
African American, Hispanic, or other race. Patients resided in
either urban or rural counties.
Patients with HCC were classiﬁed as stage 1, 2, 3, 4, or
unstaged upon diagnosis. For patients diagnosed after 2003,
cancer stage was determined by using the American Joint
Committee on Cancer 6th edition staging system. The TNM
staging system was used prior to 2003. Patient comorbidities
were assessed by using Medicare Part A or B claims for 1 year
prior to HCC diagnosis. Indicators for hepatitis B and C, alcohol-
related liver disease (ALD), and moderate-severe liver disease
(MSLD) were created. A modiﬁed Charlson comorbidity index
(CCI) was constructed by excluding liver-related risk factors, and
patients were categorized into three categories: CCI ¼ 0, 1, or
greater than 1.
Costs
Economic costs were assessed from Medicare’s perspective over
the follow-up period (i.e., patient costs, including indirect cost,
were not considered). All patients were covered under Medicare
Part A, which covers inpatient care in short- and long-stay
hospitals, skilled nursing facilities, home health, and hospice
care. All patients were covered under Part B, which covers
physician services, outpatient care, durable medical equipment,
and home health in some cases. Medicare-paid expenditures for
each patient were ascertained from Parts A and B claims data.
Total direct medical costs to Medicare per patient per month
were calculated from diagnosis until end of follow-up. Total
Medicare expenditures may be somewhat underestimated. While
several oral anticancer and antiemetic drugs are/were covered
under Medicare Part B, data for oral prescription drugs covered
under Part D were not available prior to 2007 and therefore not
incorporated into the analysis. All expenditures were inﬂated to
represent 2011 U.S. dollars by using the Bureau of Labor Statistics’
annual average Consumer Price Index for medical care.
Statistical Analysis
The frequencies and proportions of patients who underwent one,
two, three, or four or more courses of TACE were calculated. Chi-
square tests were conducted to compare patient characteristics
between the latter four cohorts because all variables were
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all-cause and HCC-related mortality in the presence of censoring.
The Kaplan-Meier method was also used to estimate the
censoring-adjusted mean time between diagnosis and repeated
TACE treatments.
Mean years survived after diagnosis was calculated as the area
under the survival curve estimated with multivariate Cox propor-
tional hazards models, stratiﬁed by TACE cohort and adjusted for
risk factors (i.e., age, sex, race/ethnicity, cancer stage, comorbidity,
hepatitis B and C, ALD, and MSLD) and other therapies undergone
(i.e., ablation, radiation, and/or chemotherapy). Stratiﬁcation
allowed for baseline hazards to vary between the TACE cohorts.
A weighted Schoenfeld residuals score test indicated nonpropor-
tional hazards for TACE cohorts and other therapies, an expected
result given heterogeneous treatment patterns over follow-up.
A multivariate weighted Cox regression was used to assess the
relative risk of all-cause and HCC-related mortality between TACE
cohorts, adjusted for the patient risk factors and other therapies
undergone. The weighted Cox regression provided a method for
estimating the average relative risk of mortality over the follow-up
period, regardless of whether that risk varied over time [20]. In
general, weighted Cox regression estimates hazard ratios averaged
over time using a weight function that reﬂects the relative
importance attached to the hazard ratios in different time periods.
An average hazard ratio (AHR) is generally deﬁned as
AHR¼
R T
t¼1 h1ðtÞ=hðtÞ
 
wðtÞf ðtÞdt
R T
t¼1 h0ðtÞ=hðtÞ
 
wðtÞf ðtÞdt
, 0 ≤ wðtÞ ≤ 1 ð1Þ
where h0(t) and h1(t) denote respective hazards of a reference group
and comparison group at time t, h(t) is the sum of these hazards at
time t, and f(t) is the density function for the events in time. Using
censored data, the weight function w tð Þ¼ S^ðtÞG^ðtÞ−1 reﬂects the
proportion of individuals affected by a hazard ratio at time t,
where S^ tð Þ and G^ tð Þ denote the Kaplan-Meier estimators of the
survival function and the censoring distribution, respectively.
AHRs estimated under the proportional hazards assumption
are obtained when w(t) ¼ 1. For “proportional” covariates,
w tð Þ¼ S^ðtÞG^ðtÞ−1≈1, and so there will be little difference between
the hazard ratio estimated under the proportional hazards
assumption and the AHR estimated by using weighted Cox
regression. Schemper et al. [20] provide greater detail on weighted
Cox regression, including a description of the weighted partial
likelihood for Cox’s regression model and conﬁrmation of its
empirical performance. We used SAS version 9.2 software (SAS
Institute, Cary, NC) for all survival analyses. Weighted Cox regres-
sion was implemented by using the SAS macro program WCM
provided on the Web by Heinze [21].
SEER-Medicare data are right-censored because the data avail-
ability is approximately 2 to 3 years old. Mean cumulative
expenditures will be underestimated because expenses after
censoring are unknown. The partitioned estimator proposed by
Bang and Tsiatis [22] was used to estimate censoring-adjusted
mean cumulative expenditures for TACE cohorts. This method
consisted of partitioning the study period into 84 monthly inter-
vals. The period was truncated at 84 months because of small
numbers after this time point (16 patients across all four cohorts).
Observed expenditures in each interval were weighted by the
inverse probability of not being censored at the beginning of the
interval, estimated by the Kaplan-Meier method. The cohort’s
mean cumulative expenditures were then calculated by summing
the inverse probability-weighted (IPW) expenditures across all
partitions and dividing by the total cohort size in the ﬁrst period.
Lin’s [23] partitioned IPW least squares regression method
was performed to estimate mean cumulative Medicare expendi-
tures for each TACE cohort adjusted for the following covariates:
age, sex, race/ethnicity, rural residence, cancer stage, Charlsoncomorbidity index, liver conditions, and receipt of ablation, che-
motherapy, and radiation therapy. Separate IPW ordinary least
squares regression analyses were estimated for each of the 84
monthly partitions. In each partition, cumulative monthly Medi-
care expenditures for each patient were regressed on indicators for
the two-, three-, and four-or-more-course cohorts and the remain-
ing covariates. The coefﬁcients on each variable were summed
across the 84 partitions to obtain the cumulative, incremental
expenditures associated with each variable [23,24]. Mean cumu-
lative expenditure for the baseline group (i.e., one course of TACE)
was then calculated by summing the estimated cumulative
intercept with the cumulative coefﬁcients on each covariate
multiplied by the sample mean of that covariate. Mean cumulative
expenditures for the two-, three-, and four-or-more-course cohorts
were obtained by summing the mean expenditures for the base-
line group and the cumulative coefﬁcient on the indicator for each
cohort, respectively. Conﬁdence intervals (CIs) for the cumulative
expenditures coefﬁcients were calculated by using a bootstrap
approach, in which the process of 84 regression analyses and the
summation of the coefﬁcients was repeated 1000 times by using
sampling with replacement [24]. We used STATA version 10.1
software (Statacorp, College Station, TX) for all cost analyses.Results
Descriptive Statistics
The study sample consisted of 1228 nontransplant/resection
patients. The largest portion of TACE recipients was diagnosed at
stage 1 (36%), the next largest portion being unstaged (26%). A total
of 16% of the patients were stage 2, 19% were stage 3, and 6% were
stage 4. A majority of the patients were between the ages of 65 and
84 years (79%), men (69%), and Caucasian (72%). Table 1 reports the
demographic and clinical proﬁle of the study sample as well as
patients stratiﬁed by the total number of courses of TACE received
in the follow-up period. Fifty-seven percent (n ¼ 696) received only
one course of TACE, 24% (n ¼ 297) received two courses, 11% (n ¼
133) received three, and 8% (n ¼ 102) received four or more
(maximum ¼ 10 courses). The median weeks between diagnosis
and ﬁrst TACE treatment was 12 weeks, 12.5 weeks between the
ﬁrst and second, 15 weeks between the second and third, and 17
weeks between the third and fourth treatments.
There were signiﬁcant differences across the strata according
to cancer stage, underlying health status (CCI), the presence of
ALD, and race. Patients who received one, two, or four or more
courses were most likely to be diagnosed at stage 1, and patients
who received three courses were most likely unstaged. There was
no substantive difference across TACE cohorts regarding propor-
tions in cancer stages 2, 3, or 4. Three or more-course patients
tended to be in better underlying health than two or fewer-course
patients and were also less likely to have ALD. Slightly larger
proportions of African Americans (49%) and other, non-Caucasian
patients (51%) were more likely to receive more than one course
of TACE compared with Caucasians (41%).
TACE patients who had undergone multiple courses of TACE
were more likely to have also undergone ablation, systemic
chemotherapy, or radiation therapy. Patients who received four
or more courses were more likely than others to have undergone
systemic chemotherapy. The utilization of repeated TACE treat-
ments or concomitant therapies may be associated with aggres-
sive treatment of tumor burden or with palliative care.
Survival Comparisons
Figure 1 presents unadjusted Kaplan-Meier estimates stratiﬁed by
the total number of courses of TACE undergone. There were
Table 1 – Clinical and demographic description of SEER-Medicare HCC patients (2000–2007) who received one or
more courses of TACE.
Variables Total 1 TACE 2 TACE 3 TACE 4þ TACE P
n ¼ 1228
(100%)
n ¼ 696
(57%)
n ¼ 297
(24%)
n ¼ 133
(11%)
n ¼ 102
(8%)
n col% n col% n col% n col% n col%
Stage 1 411 33.5 249 35.8 94 31.6 36 27.1 32 31.4 0.020
Stage 2 190 15.5 105 15.1 49 16.5 18 13.5 18 17.6
Stages 3–4† 307 25.0 168 24.1 79 26.6 33 24.8 27 26.5
Unstaged 320 26.1 174 25.0 75 25.3 46 34.6 25 24.5
CCI ¼ 0 446 36.3 247 35.5 103 34.7 56 42.1 40 39.2 0.012
CCI ¼ 1 341 27.8 186 26.7 77 25.9 38 28.6 40 39.2
CCI 4 1 441 35.9 263 37.8 117 39.4 39 29.3 22 21.6
Hepatitis B 130 10.6 69 9.9 31 10.4 14 10.5 16 15.7 0.370
Hepatitis C 448 36.5 259 37.2 113 38.0 43 32.3 33 32.4 0.529
ALD 184 15.0 117 16.8 45 15.2 x x 0.025
MSLD 150 12.2 96 13.8 31 10.4 x x 0.220
Age o65 y 231 18.8 141 20.3 56 18.9 23 17.3 11 10.8 0.130
Age 65–74 y 543 44.2 282 40.5 146 49.2 66 49.6 49 48.0
Age 75–84 y/484 y 454 37.0 273 39.2 95 32.0 44 33.1 42 41.2
Male 842 68.6 461 66.2 213 71.7 100 75.2 68 66.7 0.112
Caucasian 686 55.9 408 58.6 151 50.8 77 57.9 50 49.0 0.008
African American 66 5.4 33 4.7 22 7.4 ‡ ‡
Hispanic 197 16.0 116 16.7 52 17.5 ‡ ‡
Other 279 22.7 139 20.0 72 24.2 31 23.3 37 36.3
Ablation received 275 22.4 146 21.0 65 21.9 36 27.1 28 27.5 0.259
Systemic chemo received 298 24.3 142 20.4 83 27.9 37 27.8 36 35.3 0.001
Radiation received 154 12.5 77 11.1 40 24.0 24 18.0 13 12.7 0.151
ALD, alcohol-related liver disease; CCI, Charlson comorbidity index; chemo, chemotherapy; MSLD, moderate to severe liver disease; radiation,
includes both external beam and selective internal radiation therapies; TACE, transarterial chemoembolization.
 P value was estimated by using expanded deﬁnitions of categories, despite the aggregation of two of the categories for presentation.
† Stages 3 and 4 combined because of too few observations (n o 12) of stage 4 patients among 3 TACE and 4þ TACE patients to report.
‡ Too few 4þ TACE patients (n o 12) with ALD and MSLD to report; too few 3 and 4þ African American patients to report.
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through approximately 225 weeks as the number of TACE treat-
ments increased. Log rank tests indicate signiﬁcant differences
in cumulative survival between the 1 TACE and 2 TACE strata
(P ¼ 0.001) and the 2 TACE and 3 TACE strata (P ¼ 0.001), but not
between the 3 TACE and 4þ TACE strata (P ¼ 0.070). Using HCC-
related mortality, there are still signiﬁcant differences between
the 1 TACE and 2 TACE strata (P ¼ 0.014) and the 2 TACE and 3
TACE strata (P ¼ 0.012), and not between the 3 TACE and 4þ TACE
strata (P ¼ 0.402).
Table 2 presents the average risk of mortality over the follow-
up period, adjusting for concomitant therapies and risk factors.
There was no signiﬁcant difference in the average risk of all-
cause mortality between one-course and two-course patients
(AHR ¼ 0.92, 95% CI 0.79–1.09); however, the average risk of
HCC-related mortality was 19% less (AHR ¼ 0.81; 95% CI 0.66–
0.99). Three-course patients had a 32% lower risk of all-cause
mortality than did one-course patients (AHR ¼ 0.68; 95% CI 0.55–
0.84) and a 49% lower risk of HCC-related mortality (AHR ¼ 0.51;
95% CI 0.39–0.67). Four or more-course patients had 36% lower all-
cause mortality risk (AHR ¼ 0.64; 95% CI 0.52–0.79) and 54% lower
HCC-mortality risk (AHR ¼ 0.46; 95% CI 0.39–0.63). Chi-square
tests indicate signiﬁcant difference in all-cause (/HCC-related)
mortality between two-course and three-course patients
(P ¼ 0.005/P ¼ 0.002) but not between three-course and four or
more-course patients (P ¼ 0.663/P ¼ 0.606). The models were
expanded to delineate between patients who received fourcourses of TACE and ﬁve or more courses, but no further
reduction in mortality was associated with the fourth treatment,
nor with ﬁve or more (results not shown).
Differences in average mortality risk should not be interpreted
as incremental treatment effects because patients could not be
sufﬁciently randomized into TACE cohorts. HCC is an aggressive
and complex disease that is difﬁcult to evaluate and treat [5,7].
There is no way to discern whether a patient was assigned
multiple courses of TACE as part of a patient-speciﬁc treatment
protocol determined at the outset of treatment. In the real world,
a repeated course of TACE may have been prescribed in an ad hoc
manner, according to patient-speciﬁc tumor response to the prior
course and eligibility for further treatment. For instance, Figure 2
illustrates censoring-adjusted means for the weeks between HCC
diagnosis and discontinuation of TACE, as well as for weeks
survived. Expectedly, patients who had received more courses of
TACE tended to do so over a longer span of time. On average,
however, patients who received one, two, or three total courses of
TACE survived similar lengths of time after discontinuing TACE,
between 13.6 and 14.7 months (59–64 weeks); 11.5 months (50
weeks) for four or more-course patients.
The all-cause (/HCC-related) mortality risk for TACE patients
who had also undergone ablation was lower than that for non-
ablation patients (AHR ¼ 0.63, 95% CI 0.53–0.74/AHR ¼ 0.56, 95% CI
0.45–0.69) (Table 2). Both systemic chemotherapy (AHR ¼ 0.58;
95% CI 0.47–0.72) and radiation therapy (AHR ¼ 0.67; 95% CI 0.52–
0.86) had lower HCC mortality. Patients diagnosed at later stages
Fig. 1 – Patient survival (in weeks from diagnosis), per number of TACE courses; unadjusted models. HCC, hepatocellular
carcinoma; TACE, transarterial chemoembolization.
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greater risk of mortality in the follow-up period. “Other races”
had lower risk of all-cause mortality than did Caucasians (AHR ¼
0.83; 95% CI 0.70–0.99). Patients aged 65 to 74 years (AHR ¼ 1.36;
95% CI 1.03–1.80) showed higher HCC mortality, and patients aged
75 to 84 (AHR ¼ 1.32; 95% CI 1.06–1.64) showed higher all-cause
mortality. No other patient characteristics were signiﬁcant fac-
tors for survival.
Cumulative Medicare Expenditures
The unadjusted IPW average for cumulative Medicare expendi-
tures per patient was $71,029 if one course of TACE was under-
gone, $101,402 for two courses, $110,538 for three courses, and
$143,961 for four or more courses (Figure 2). Table 3 presents the
average cumulative Medicare expenditures for the TACE cohorts,
adjusted for censoring, concomitant therapies, and clinical and
demographic characteristics. Mean years survived was calculated
by using the adjusted survival curves shown in Figure 3. One-
course patients survived an average 1.86 (95% CI 1.82–1.90) years
following diagnosis and incurred an average $74,788 (95% CI
$71,890–$77,686). Two-course patients lived an average 2.09
(95% CI 2.05–2.13) years and incurred $101,126 (95% CI $94,395–
$107,856). Three-course patients lived 2.81 (95% CI 2.66–2.97)years and incurred $111,776 (95% CI $101,931–$121,621). Four or
more-course patients lived 3.06 years on average and incurred
$148,878 (95% CI $136,346–$161,409).
If mortality is restricted to be HCC-related, then a consistent
survival advantage associated with additional courses of TACE is
no longer evident. One-course patients survived an average 3.24
(95% CI 3.12–3.36) years after diagnosis, while two-course patients
survived only 2.86 (95% CI 2.77–2.95) years after diagnosis. Three-
course patients survived an average 4.09 years, while four or
more-course patients survived 3.82 (95% CI 3.55–4.10) years.Discussion
Prior research has examined the economic burden of caring for
HCC in the United States [16]; however, to our knowledge, this
study is the ﬁrst to examine the long-term costs associated with
repeated applications of TACE in treating the disease. In an era of
concern over wasteful spending in the health care sector, there is
greater focus by payers and providers to balance the effective use
of allocated budgets with sufﬁcient intensity of therapy for their
patients. Hence, health care organizations have an interest in
knowing the costs of TACE as it is applied in the real-world
Table 2 – Average risk of all-cause and HCC-related mortality over the follow-up period: Results from
multivariate weighted Cox regression models.
Covariates All-cause mortality HCC-related mortality
AHR 95% CI AHR 95% CI
1 TACE Reference
2 TACE 0.92 0.79–1.09 0.81 0.66–0.99
3 TACE 0.68 0.55–0.84 0.51 0.39–0.67
4þ TACE 0.64 0.52–0.79 0.46 0.39–0.63
No ablation Reference
Ablation 0.63 0.53–0.74 0.56 0.45–0.69
No systemic chemo Reference
Systemic chemo 0.90 0.78–1.04 0.58 0.47–0.72
No radiation Reference
Radiation 0.89 0.75–1.05 0.67 0.52–0.86
Stage 1 Reference
Stage 2 1.13 0.94–1.36 0.98 0.73–1.33
Stage 3 1.82 1.49–2.22 2.18 1.70–2.79
Stage 4 1.72 1.24–2.40 2.38 1.68–3.39
Stage unknown 1.09 0.89–1.32 1.58 1.26–1.99
CCI ¼ 0 Reference
CCI ¼ 1 0.97 0.82–1.15 0.84 0.68–1.04
CCI 4 1 1.00 0.82–1.22 0.86 0.69–1.08
No hepatitis B Reference
Hepatitis B 0.81 0.64–1.04 0.74 0.54–1.01
No hepatitis C Reference
Hepatitis C 1.14 0.98–1.32 1.02 0.84–1.22
No ALD Reference
ALD 1.12 0.90–1.40 1.15 0.88–1.50
No MSLD Reference
MSLD 1.62 1.28–2.05 1.38 1.00–1.90
Age o65 y Reference
Age 65–74 y 1.20 0.98–1.48 1.36 1.03–1.80
Age 75–84 y 1.32 1.06–1.64 1.33 0.99–1.78
Age 484 y 1.31 0.75–2.29 1.74 0.90–3.37
Female Reference
Male 1.09 0.94–1.26 1.09 0.90–1.32
Caucasian Reference
African American 1.26 0.97–1.64 1.27 0.86–1.87
Hispanic 0.89 0.72–1.11 0.90 0.70–1.17
Other race/ethnicity 0.83 0.70–0.99 0.90 0.72–1.12
Censored 185 of 1228 652 of 1228
AHR, average hazard ratio estimated by using weighted Cox regression model; ALD, alcohol-related liver disease; CCI, Charlson comorbidity
index; chemo, chemotherapy; CI, conﬁdence interval; HCC, hepatocellular carcinoma; MSLD, moderate to severe liver disease; radiation,
includes both external-beam and selective-internal radiation therapies; TACE, transarterial chemoembolization.
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 7 6 0 – 7 6 8 765practice environment, especially in the population for which
TACE is most treated.
This analysis was a retrospective study of Medicare beneﬁ-
ciaries who resided within SEER-registry areas and were diag-
nosed with HCC between 2000 and 2007. Of the 1228 patients
who received at least one TACE treatment, never received
transplant or resection, and met the inclusion criteria, less
than half had undergone multiple courses of TACE; 24%
(n ¼ 297) received two courses, 11% (n ¼ 133) received three
courses, and 8% (n ¼ 102) received four or more (up to 10
courses). Adjusted average cumulative Medicare-paid expendi-
ture for one-course patients after diagnosis was $74,788 (95% CI
$71,890–$77,686). Cumulative expenditures were 35% higher for
two-course patients, 50% higher for three-course patients, and
nearly double with four or more courses. Balancing expendi-
tures with additional years of life showed that spending driven
by greater survival may explain a portion of the increased
expenditures. One-course patients lived an average 1.86 (95%CI 1.82–1.9) years after diagnosis. Two-course patients lived
about 12% longer than did one-course patients, three-course
patients 51% longer, and four or more-course patients 65%
longer. Average years survived did not consistently increase
with additional courses of TACE when we analyzed only HCC-
related mortality.
It is unlikely that a comparison of average rates of Medicare
spending would be reﬂective of the value of repeated courses of
TACE. While it is inappropriate to attribute all expenditures to
TACE, it is also inappropriate to attribute all life to TACE. First,
adjusting for concomitant therapies and patient risk factors, the
average risk of all-cause mortality over the follow-up period was
not signiﬁcantly lower with two courses of TACE versus only
one course of TACE. The average risk of mortality was lower
for three or more courses versus one course, but no signiﬁ-
cant difference was found between three courses and four
or more courses. Using HCC-related mortality, average risk
over follow-up for two, three, or four or more courses was
Fig. 2 – Mean weeks from HCC diagnosis until ﬁnal course of TACE and until mortality, with unadjusted average cumulative
cost per patient (2011 US $).* TACE, transarterial chemoembolization.*Means were calculated by using Kaplan-Meier analyses
to adjust for censoring. Unadjusted average cumulative cost per patient estimated by using Bang and Tsiatis’s [22] method for
estimating medical costs with censored data.
Table 3 – Adjusted average cumulative Medicare expenses (2011 US $) and adjusted mean years survival
associated with multiple TACE treatments for HCC.
1 TACE 2 TACE 3 TACE 4þ TACE
Adjusted average cumulative Medicare $74,788 $101,126 $111,776 $148,878
expenses (95% CI) ($71,890–$77,686) ($94,395–$107,856) ($101,931–$121,621) ($136,346–$161,409)
Using all-cause mortality
Adjusted mean years survived after diagnosis 1.86 2.09 2.81 3.06
(95% CI)† (1.82–1.90) (2.05–2.13) (2.66–2.97) (2.95–3.18)
Using HCC-related mortality
Adjusted mean years survived after diagnosis 3.24 2.86 4.09 3.82
(95% CI)† (3.12–3.36) (2.77–2.95) (3.75–4.44) (3.55–4.10)
CI, conﬁdence interval; HCC, hepatocellular carcinoma; TACE, transarterial chemoembolization; 4þ, four or more courses of TACE undergone
in the follow-up period (maximum 10).
 To adjust for censoring and patient characteristics, expenditure coefﬁcients for TACE cohorts were estimated by using partitioned, inverse
probability-weighted, multivariate least squares regression. Estimates represent the additional cumulative Medicare expenditures compared
with patients who received only one TACE. The model includes as covariates age, sex, race, Hispanic ethnicity, rural residence, cancer stage,
Charlson comorbidity index, liver conditions, and receipt of ablation, chemotherapy, and external-beam or selective-internal radiation
therapy. Estimates were calculated by using the bootstrap approach, in which the process of performing 84 (monthly) partitioned regression
analyses and summing coefﬁcients across partitions was repeated 1000 times by using sampling with replacement.
† Cumulative years survived calculated as the total area under the respective adjusted survival curve, divided by 52 weeks per year, estimated
by using Cox proportional hazards models stratiﬁed by TACE cohorts.
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 7 6 0 – 7 6 8766signiﬁcantly lower than for one-course patients, yet there was
also no signiﬁcant difference between three and four or more
courses of TACE.
Second, HCC is an aggressive disease that is difﬁcult to
evaluate and treat. SEER-Medicare is limited in nuanced clinical
data used by physicians to determine severity or progression of
the disease and may preclude patients from further treatment.
Thus, patients who had undergone repeated courses of TACE as a
part of a patient-speciﬁc treatment protocol could not be
delineated from patients prescribed more than one course of
TACE according to continued eligibility for further treatment or
tumor response to the prior course. For instance, we found
striking similarity across all TACE cohorts in the unadjusted
average time of survival after TACE is discontinued (between
13.6 and 14.7 months for one to three courses and 11.5 with four
or more courses). Much of the survival advantage across cohortstended to accrue prior to the ﬁnal course of TACE. If it is assumed
that further TACE treatments are undergone through patient/
physician choice, then any survival beneﬁt of repeated TACE may
tend to be realized until sufﬁcient progression of the disease
facilitates discontinuing treatment. Conversely, if greater survival
is reﬂective of only selection of the ﬁttest patients into further
TACE treatments, then clinical beneﬁts associated with repeated
TACE would be overstated.
An advantage of SEER-Medicare database is that it allowed
observation of the long-term survival and medical expenditures
of cancer patients. Yet, clinical data are limited to that which can
be obtained from Medicare claims or provided by SEER at the time
of cancer diagnosis. While observed risk factors were largely
balanced across the TACE groups, unobserved differences may
have confounded cost and mortality comparisons between the
four TACE groups.
Fig. 3 – Patient survival (in weeks from diagnosis), per number of TACE courses; adjusted models.* TACE, transarterial
chemoembolization. *Adjusted for age, sex, race, Hispanic ethnicity, cancer stage, Charlson comorbidity index, liver
conditions, and receipt of ablation, chemotherapy, and radiation therapy.
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estimated. While several oral anticancer and antiemetic drugs
are/were covered under Medicare Part B, data for oral prescription
drugs covered under Part D were not available prior to 2007 and
therefore were not incorporated into the analysis. We did not
anticipate costs to be underestimated for any particular TACE
cohort more than others. IPW least squares regression was used
to estimate cumulative costs in the presence of censoring in the
sample. Estimators based on IPW can sometimes be biased if
censoring is large or dependent on covariates [25]. Only 15%
(n ¼ 183) of the observations were censored in this sample,
and the correlation coefﬁcient between censored observations
and any covariate was relatively low ( ρ ¼ 0.14 for stage 1, and
0.00 o ρ o 0.10 for all other variables). The bootstrap procedure
was used to approximate the variance of the regression coef-
ﬁcients. Despite no formal proof of consistency of the bootstrap
estimator in this setting, we followed the suggestions and
examples of other authors using bootstrap in similar settings
[24–27]. As argued by Grifﬁths et al. [26], further research isneeded regarding the strengths and weaknesses of bootstrap for
long-term cost estimators.
Physician and patient choice is an important determinant of
quality cancer care, but, from a policy standpoint, the current
health care environment necessitates treatment choice to be
balanced with considerations of costs. Our ﬁndings show that
Medicare expenditures doubled between one and four or more
TACE treatments, but expenses were distributed over more than
an additional year of life. Our results may have implications for
patients and Medicare as well as health care organizations
concerned with the efﬁcient use of resources for treating the
growing population of patients with HCC. Data limitations pre-
vented methods for the randomization of patients necessary for
an unbiased cost-effectiveness analysis of repeated TACE treat-
ments. However, cost-effectiveness analysis through randomized
controlled trials would be unethical. In the absence of complete
comparative and cost-effectiveness evidence of TACE, our results
provide data on the association between multiple TACE treat-
ments, cumulative expenditures, and survival.
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